Thymalfasin

DRUG12 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Jia Fan, Zhejiang Provincial People's Hospital, Hangzhou Cancer Hospital, William B. Ershler, MD

Conditions

Advanced Solid TumorCOVID-19Colorectal CancerColorectal NeoplasmsCovid19Curable Hepatitis B Virus-Related Hepatocellular CarcinomaEsophageal CancerEsophagogastric Junction Adenocarcinoma

Phase 1

The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

CompletedNCT00001036

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Target: 12Updated: 2008-07-30

Phase 2

Abscopal Effect for Metastatic Colorectal Cancer

WithdrawnNCT02535988

Zhejiang Provincial People's HospitalColorectal Cancer, Metastatic Colorectal Cancer, Thymalfasin

Start: 2015-09-30End: 2017-12-31Updated: 2023-09-21

Abscopal Effect for Metastatic Small Cell Lung Cancer

WithdrawnNCT02542137

Zhejiang Provincial People's HospitalRadiotherapy, Small Cell Lung Cancer, Thymalfasin

Start: 2015-09-30End: 2019-12-31Updated: 2019-03-21

Abscopal Effect for Metastatic Non-small Cell Lung Cancer.

WithdrawnNCT02542930

Zhejiang Provincial People's HospitalMetastatic Non-small Cell Lung Cancer, Non-small Cell Lung Cancer, Radiotherapy +1

Start: 2016-01-31End: 2019-12-31Updated: 2019-03-26

SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer

Hangzhou Cancer HospitalEsophageal Cancer, Metastatic Esophageal Cancer, Stereotactic Body Radiation Therapy +1

Start: 2016-01-31End: 2018-12-31Target: 29Updated: 2017-11-28

Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients

CompletedNCT04428008

William B. Ershler, MDCOVID-19

Start: 2021-01-12End: 2023-01-19Updated: 2025-10-09

Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection

TerminatedNCT04487444

Rhode Island HospitalCovid19

Start: 2020-09-10End: 2023-02-03Updated: 2023-02-14

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow UniversityAdvanced Solid Tumor, Refractory Tumor

Start: 2023-04-01End: 2025-12-31Target: 60Updated: 2023-03-30

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Active, not recruitingNCT06056804

Beijing Friendship HospitalLocally Advanced Rectal Cancer

Start: 2024-01-03End: 2027-07-01Target: 20Updated: 2025-04-02

Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

RecruitingNCT06461910

Zekuan XuEsophagogastric Junction Adenocarcinoma, Gastric Cancer

Start: 2024-06-14End: 2027-12-01Target: 30Updated: 2026-03-03

Phase 4

Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection

Jia FanCurable Hepatitis B Virus-Related Hepatocellular Carcinoma

Start: 2015-01-31End: 2018-10-31Target: 360Updated: 2014-11-21

Unknown Phase

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer

Beijing Friendship HospitalColorectal Neoplasms

Start: 2023-09-20End: 2024-03-30Target: 26Updated: 2023-09-06

Related Papers

Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial

BMC Medicine2026-02-26

Efficacy and Safety of PRaG Therapy in Elderly Patients with Advanced Malignant Tumors: A Prospective, Multicenter Clinical Study Protocol (PRaG 9.0 Study)

Technology in Cancer Research & Treatment2025-06-01

Novel dynamic circulating biomarkers for predicting therapeutic efficacy of PRaG regimen in advanced refractory solid tumors.

Journal of Clinical Oncology2025-05-28

Thymosin alpha-1–enhanced PRaG regimen: A novel approach to boosting immune dynamics and therapeutic efficacy in advanced solid tumors.

Journal of Clinical Oncology2025-05-28

Safety and efficacy evaluation of neoadjuvant chemoradiotherapy plus thymalfasin and tislelizumab for treating MSS/pMMR locally advanced rectal cancer.

Journal of Clinical Oncology2025-05-28

Efficacy and safety of anti-PD-1 combined with thymosin and SOX in neoadjuvant treatment of cStage III gastric or esophagogastric junctional adenocarcinoma (NAPTSOX24): A prospective, open-label, single-arm, phase II clinical study.

Journal of Clinical Oncology2025-05-28

A precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumors: An open-label, prospective, multicenter clinical study (PRaG 5.0 study).

Journal of Clinical Oncology2024-06-01

Efficacy and safety of neoadjuvant chemoradiotherapy combined with tislelizumab and thymalfasin in the treatment of locally advanced lower rectal cancer.

Journal of Clinical Oncology2024-06-01

Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study)

BMJ Open2024-03-012 citations

A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection

The Journal of Infectious Diseases2022-09-0111 citations

A multicenter, randomized, observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection – first announcement of the protocol

Expert Opinion on Biological Therapy2015-06-2210 citations